Introduction and Aims: Aldosterone-to-renin ratio (ARR) is believed to be a more robust screening test than aldosterone levels for primary aldosteronism, and it could be an index for inappropriate aldosterone activity and salt sensitivity. Recently, in a community-based longitudinal study in United States, aldosterone was associated with incident CKD and microalbuminuria independent of traditional risk factors. However, the influence of ARR on the development of CKD has not been reported previously. Therefore, the present study was conducted to examine the association of plasma renin activity (PRA), plasma aldosterone concentration (PAC) and ARR with the development of CKD in a general Japanese population. Methods: We conducted a longitudinal observational study involving 689 participants from a general Japanese population (mean age 58.2 years; 68.5% women) who did not have CKD and were not receiving antihypertensive medication at baseline. The estimated glomerular filtration rate (eGFR) was calculated from serum creatinine levels and CKD was defined as eGFR < 60 ml/ min/1.73 m2 and/or dipstick-positive proteinuria. The associations of baseline plasma renin activity (PRA), plasma aldosterone concentration and ARR with the development of CKD were examined using Cox proportional hazard regression analysis adjusted for sex, age, body mass index, smoking, drinking, history of hypercholesterolemia, diabetes mellitus, and cardiovascular disease, systolic blood pressure, and baseline eGFR. Results: During a mean 9.1-year follow-up, 118 subjects developed CKD. Mean values were 127.9 ± 13.2/71.9 ± 8.7 mmHg for systolic/diastolic blood pressure levels, 0.82 ± 0.13 mg/dl for serum creatinine by the Jaffe assay, and 87.3 ± 17.5 ml/min/ 1.73 m2 for eGFR. The median (25-75th percentiles) values were 1.1 (0.6-1.9) ng/ ml/h for PRA, 65 (50-81) pg/ml for PAC, and 56 (35-97) pg/ml per ng/ml/h for ARR. A 1-standard deviation increment in the natural log-transformed (ln) ARR was positively associated with the incidence of CKD (hazards ratio 1.29; P=0.012). LnPRA showed an inverse association (hazards ratio 0.76; P=0.007). However, PAC was not associated with CKD. Individuals who developed CKD had significantly lower baseline PRA (0.97 vs. 1.14 ng/ml/h; P=0.03) and higher baseline ARR levels [66.6 vs. 56.8 ( pg/ml)/(ng/ml/h); P=0.02] than those who did not. Conclusions: Lower PRA and higher ARR were associated with the development of CKD in a general population. Furthermore, individuals who developed CKD had significantly lower baseline levels of PRA and higher baseline levels of ARR than those without CKD, despite no differences in PAC. Such a form of low PRA and "normal" PAC is called a relative aldosterone excess, which might increase the salt sensitivity of blood pressure due to inappropriate sodium and fluid retention. The present results suggest that PRA and ARR may be an independent predictor of CKD, and that salt sensitivity indicated by relative aldosterone excess may contribute to an increased risk of CKD.
Introduction and Aims: Chronic kidney disease (CKD) remains asymptomatic until its late stage. There is only little information on the association of renal function with subclinical atherosclerosis as depicted by carotid intima media thickness (cIMT). The aim of the present study was to examine the association of cIMT with various serum markers of renal function in a large population based study. Methods: The Study of Health in Pomerania (SHIP) is a cross-sectional, population based study in the North East of Germany. Data from 2367 individuals (1199 males) aged 45 years or older were available for analysis. Creatinine clearance was calculated by the Cockroft-Gault, Jelliffe, Wright and the abbreviated Modification of Diet in Renal Disease formulae. Women and men were analyzed separately. Results: 240 males (20.0%) and 244 females (20.9%) showed serum creatinine values above the normal range. Males and females with high serum creatinine had higher serum HbA1C levels, pulse pressure, BMI, and serum uric acid levels. After adjusting for confounding factors, multivariable analysis revealed that in males, raised serum creatinine levels were independently associated with carotid IMT (non-standardised β-coefficient 0.0274, 95% CI 0.005-0.050, p= 0.018). However, we could not find an association for raised serum creatinine levels in women nor for reduced values of calculated creatinine clearances in either sex. Conclusions: We found a gender-specific relation between impaired renal function measured by serum creatinine and cIMT. With rising serum creatinine, the exponential relationship between creatinine and eGFR leads to relatively higher increases in serum creatinine for each mL loss of GFR and thus creatinine in already established renal failure may be more sensitive biomarker for renal function than eGFR. Ternopil University Hospital, Ternopil, Ukraine
FP152 CAROTID ARTERY REMODELING AND ENDOTHELIAL DYSFUNCTION IN PREDIALYSIS PATIENTS WITH CHRONIC KIDNEY DISEASE
Introduction and Aims: The processes of carotid artery remodeling in patients under the predialysis period of chronic kidney disease (CKD), particularly with conditions of cardiac valve calcification (CVC), were not asserted enough. Not clearly determined remains the role of endothelial dysfunction (ED), especially of nitric oxide (NO) system, in mechanisms of extracranial vessels calcification as a constituent of arterial remodeling in predialysis patients. The purposes of the current study were to research the character of structural and functional changes of carotid arteries (CA) in patients with predialysis stages of CKD according to presence/ absence of CVC, and to establish the association of calcified plaques with indices of functional state of endothelium. 38.9%, stage IV: 18.0%, stage V: 6.6%) CKD patients. All subjects underwent echocardiographical examination for detection of valve calcification. Ultrasound scanning and dopplerography of CA included assessment of plaque morphology (Gray-Weale classification), measurement of common carotid artery intima-media thickness (C?? IMT), diameter (CCA D), wall/lumen ratio (CCA IMT/D), degree of stenosis, utilizing standardized approaches, proposed in consensuses (Grant E.G. et al., 2003; Touboul P.J. et al., 2007) . Vasomotional function of brachial artery (BA) was assessed using a test with reactive hyperemia (flow-mediated dilatation (FMD). Plasma content of nitrites (NO2-), nitrates (NO3-) and amount of circulating endothelial cells (CECs) (Hladovec J., 1978) were measured as markers of ED. Va San Diego Healthcare System and University of California San Diego, Ca, U.S.A,
Introduction and Aims:
We have previously demonstrated that in patients with CKD the presence of RH is associated with poor renal outcomes. In these patients, ABP is mandatory to rule out pseudo-resistant hypertension (white coat hypertension, WCH/ RH). Whether the prognostic role of daytime and nighttime BP found in hypertensive subjects also applies to CKD patients with RH is unknown. This study investigates whether combining information from ABP and RH status enhances risk stratification of CKD. Methods: We prospectively evaluated 376 consecutive hypertensive CKD patients followed for at least 6 months in 3 Nephrology clinics in Italy from 1/2003 to 12/ 2005 and adherent to prescribed therapy. RH was defined as office blood pressure (OBP) =130/80 mm Hg despite =3 drugs at full dose including a diuretic. WCH was the presence of OBP =130/80 mm Hg and ABP within normal range (day <135/85 and night <120/70 mmHg) while sustained hypertension (SH) was uncontrolled OBP and ABP. Patients were categorized according to the presence of WCH and RH in four groups: WCH/no RH (controls), WCH/RH, SH/no RH and SH/RH. Primary end points were time to renal death (either ESRD or death) and time to fatal and nonfatal CV events. Results: Compared to WCH/no RH, SH/RH were older (69±11 vs 65±14 yrs) more frequently males (61 vs 51%) with larger prevalence of diabetes (66 vs 27%) and history of CV events (47 vs 27%); SH/RH patients also had higher BMI (31±6 vs 28 ±5 kg/m2), higher proteinuria (1.8±2.4 vs 0.4±0.7 g/day) and lower eGFR (35±18 vs 48±17 mL/min/1.73m2) (P<0.01 for all comparisons). Patients with SH had systolic OBP higher than those with WCH (153±17 vs 146±15 mmHg). Among those with SH, systolic daytime and nighttime ABP were significantly higher in RH (146±15 and 141±19 mmHg) than in no RH (139±14 and 130±16 mmHg). A higher prevalence of non-dipping was observed in SH/RH compared to SH/no RH (77 vs 62%). During follow-up (median 49 months, IQR 34-60), we registered 89 CV events and 132 renal deaths. To further evaluate the prognostic role of RH, Cox's analyses were performed using ABP as continuous variable. Adjustment for nighttime ABP, but not daytime, abolished the prognostic role of RH on either outcome. Conclusions: In patients with CKD and elevated OBP, ABP identifies patients with WCH/RH who are at very low risk for renal and CV events compared to SH/RH. Increased CV/renal risk in SH/RH is associated with higher nocturnal ABP. These results demonstrate the incremental benefit of ABP and RH in predicting CV/renal events and raise the question whether nocturnal hypertension should become a major target of therapy in CKD patients with RH. Table 1 Adjusted for age, gender, BMI, diabetes, previous CV events, Hb, proteinuria and GFR.
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Introduction and Aims:
In the large conduit arteries, elastin is important in maintaining vascular compliance. Studies in animal models suggest that elastin degradation may promote arteriosclerotic vascular changes. There is already a well-established link between aortic stiffening and mortality. Elastin degradation is mediated by several proteases including matrix metalloproteinase-2 and cathepsin S. Elastin turnover may be inferred by measuring serum levels of elastin-derived peptides. Methods: We analysed the serum concentration of matrix metalloproteinase-2, cathepsin S, elastin-derived peptides, their endogenous inhibitors, tissue inhibitors of metalloproteinase-1 and -2, cystatin C, and aortic pulse wave velocity in 200 patients with stage 3 & 4 chronic kidney disease, and then serially in a subgroup of 65 patients over 36 months. We compared baseline biochemitries to a group of 152 healthy controls. Results: Serum matrix metalloproteinase-2, cathepin S and elastin-derived peptide levels were higher in CKD patients compared to healthy controls of similar age, and levels increased at a higher rate than in non-CKD suffers. All 3 markers of elastin degradation were independently associated with baseline aortic pulse wave velocity and changes in stiffness over the follow-up period. Higher matrix metalloproteinase-2 (odds ratio per 1D increase = 3.11, P=0.001) and elastin-derived peptide levels (odds ratio per 1D increase = 1.98, P=0.018) were also independently associated with pre-existing cardiovascular disease . In multivariable Cox regression analysis, higher serum elastin-derived peptide levels were associated with increased all-cause mortality (hazard ratio per 1SD increase = 1.78, P=0.021) after adjustment for known cardiovascular and renal risk factors. Conclusions: In pre-dialysis chronic kidney disease, elastin degradation is a major determinant of aoritc stiffness and is associated with all-cause mortality. Pusan National University Hospital Introduction and Aims: Brachial-ankle pulse wave velocity (BaPWV) is a measure of arterial stiffness and known to be an independent predictor of cardiovascular disease (CVD) in several disease populations including chronic kidney disease (CKD). But little is known about which individual factors are associated with arterial stiffness in CKD patients. Methods: We retrospectively reviewed the 293 patients who had visited health promotion center in a single community. The patients were divided into 2 group which are CKD group (n=99, estimated glomerular filtration rate (eGFR): 15-59 mL/ min) and non-CKD group (n=194, eGFR = 60 mL/min). Baseline characteristics (age, sex, diabetes, hypertension, smoking, eGFR, ankle-brachial index (ABI), intimal thickness (IMT) of carotid artery, systolic/diastolic blood pressure, body mass index (BMI) and various biochemical blood examinations including cystatin C, homocystein) were evaluated in each patient. The arterial stiffness was measured by BaPWV and which factor correlated with arterial stiffness was evaluated in each group. Results: In multiple linear regression analysis, age (β=0.360, p<0.001), systolic blood pressure (SBP) (β=0.369, p<0.001), and presence of DM (β=0.328, p<0.001) were independently associated with BaPWV in non-CKD group after adjustment for other confounding factors. However, in CKD group, not only age (β=0.235, p=0.001), SBP (β=0.243, p=0.004) , and the presence of DM (β=0.064, p=0.02), but also eGFR (β=-0.235, p=0.01), serum homocystein (β=0.106, p=0.02), and serum cystatin C (β=0.155, p=0.008) contributed to BaPWV independently after adjustment for other confounding factors. Conclusions: This study showed the eGFR, serum cystatin C and, serum homocystein were independently associated with arterial stiffness only in CKD group, not in non-CKD group. Because arterial stiffness is a strong predictor of CVD, the result of this study demonstrates that decreased GFR and increased level of serum cystatin C/homocystein could increase the risk of CVD by deteriorating the arterial stiffness in CKD patients. Pearson correlation coefficient was calculated between BSA and m-GFR (ml/min), as well as Height and m-GFR (ml/min) to establish how strong the association was. P values <0.05 were considered significant. Results: BSA-GFR in the subgroup with a BSA = 2 m 2 underestimated GFR with a bias up to -20.76 ml/min (-23.59%), and the opposite effect occurred in the subgroup of BSA < 1.60 m 2 where it causes an overestimation of GFR with a bias of 10.08 ml/ min (11.46 %). Indexing GFR for height also causes bias but to a much lesser extent. Bias in the subgroup of BSA = 2 was -6.67 ml/min (-7.59 %) whereas bias in subgroup with BSA < 1.6 was 3.99 ml/min (4.53%). GFR increased with BSA in men but not in women. There was an overall correlation between BSA and m-GFR of 0.52 and 0.44 between Height and m-GFR. Intercept was BSA= 1.4381 + 0.004 x ABS-GFR and Height = 156.63 + 0.14 x ABS-GFR. Conclusions: BSA is not a good normalisation index in patients with extreme body sizes. Therefore, we recommend clinicians to use the GFR as ml/min values instead of ml/min per 1.73m2 when treating individuals. Introduction and Aims:Chronic Kidney Disease (CKD) is an emerging public health problem worldwide.Nevertheless, the pattern of patients with CKD evaluated by nephrologists and the assessmentof complications such as Secondary Hyperparathyroidism (SHPT) remains country and manytimes physician specific. PRESTAR sought to assess the characteristics of the CKD stages 3-5(not on dialysis) population that is followed up in Nephrology clinics in Greece. Secondarily,we examined the habitual clinical practices related to patient referrals and PTH measurementfrequency in the same patient population. Methods: This is a multicentre, epidemiological cross-sectional study conducted in outpatientNephrology clinics at different geographic regions in Greece during 2009-10. Data on referralpatterns, demographics, medical and medication history, blood pressure, blood urea,creatinine blood levels, PTH blood levels and estimated creatinine clearance were collected.The Cockroft Gault rather than the MDRD equation was selected because at the time of thestudy, it was the most commonly used estimating method to assess renal function and CKDstage by Greek nephrologists. Adult consecutive CKD patients followed in Nephrologyoutpatient clinics, older than 18 years of age, able to give informed consent were included;patients with acute kidney injury or any serious disease with expected survival of less than 12months were excluded. Continuous variables were summarized with means and standarddeviations, while categorical variables were presented with frequency tables. Associationsbetween variables were assessed with t -tests and chi square statistics. Results:1501 patients in 9 clinics were included. Patient's demographics were as follows: 45.1%(677/1501) were female, age 66.2 ± 14.6 years, BMI 28.8 ± 5.5 kg/m2, Systolic BloodPressure: 137.1 ± 17.8 mmHg, Diastolic Blood Pressure: 80.5 ± 10.4 mmHg, serumCreatinine: 2.0 ± 1.1 mg/dl. A sizeable minority of patients (26.7%) had early CKD (stages 1-2). The remaining population was : 59.9% CKD stage 3, 33.6% CKD stage 4 and 6.6% CKD stage 5. Four renal diagnoses accounted for 75.3% of CKD cases: diabetic nephropathy(29.7%), vascular disease (25.3%), glomerular disease (16.3), interstitial nephritis (5%).36.5% of patients were self referred, while the remaining had been referred by a physician ofanother specialty. Four specialties accounted for the bulk of referrals: Internal medicine(48.9%), Diabetology (10.1%), Cardiology (6.9%) and Urology (6.9%), with no relationshipbetween CKD stage and referring specialty. PTH was assessed in 46.6% of patients and thelikelihood of obtaining a PTH measurement was higher in advanced CKD stage (37.1, 43.8,57.2 and 70.6 in stages 1-2,3,4,5 respectively, p<0.001). PTH progressively increased withadvancing stage of CKD 65. 4 ± 41.4, 73.0 ± 50.4, 108.6 ± 73.7, 178.4 ± 149.4, 296.1 ± 236.3( p<0.001) Conclusions:A large minority of Greek patients present as self referrals to Nephrology clinics, while alarge number of patients exhibit laboratory evidence of SHPT even in early CKD stages.Public Health initiatives are urgently required to raise awareness of CKD and itscomplications (SHPT) among non nephrologists in the Greek healthcare system. Table 2 Comparison of correlation between body surface area and glomerular filtration rate as absolute and indexed values *:p<0.05; **p<0.01; ***p<0.001; NS not significant GFR: glomerular filtration rate; BSA: Body surface area.
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FP156 Table 3 Comparison of correlation between body surface area and glomerular filtration rate as absolute and indexed values *:p<0.05; **p<0.01; ***p<0.001; NS not significant GFR: glomerular filtration rate; BSA: Body surface area; BMI: body mass index, Mean Height in centimeters. 
FP158 OXIDATIVE STRESS AND KIDNEY EFFECTS IN WORKERS WITH LOW OCCUPATIONAL EXPOSURE TO CADMIUM
University of Louvain
Introduction and Aims:Brazing with cadmium (Cd) containing silver solder expose workers to Cd. Recent studiessuggest adverse health effects at Cd concentrations in urine below 2.0 μg/g creatinine. Theaim of this study was to assess Cd, renal markers, and oxidative stress markers in suchworkers. Methods: Concentrations of Cd in blood (Cd-B) and urine (Cd-U) were determined in 36 refrigerationindustry workers frequently brazing with cadmium containing silver alloys and in 29 non-exposed control subjects. Concentrations of renal markers (NAG, IAP, μ-Alb, β2-MG, RBPin urine) and oxidative stress markers (d-ROM, GPX, SOD in blood and 8-OHdG in urine)were measured as well. Results: Exposed workers had significantly higher concentrations of Cd-B and Cd-U as compared withnon-exposed subjects: 1.63 μg/l (95% CI: 1.29-2.06) and 0.82 μg/g creatinine (95% CI: 0.52-1.27), respectively, versus 0.21 μg/l (95% CI: 0.15-0.29) and 0.14 μg/g creatinine (95% CI:0.10-0.19), respectively. Pearson correlation analysis showed a statistically significantpositive correlation between IAP and Cd in blood and urine. In addition, a statisticallysignificant positive correlation was found between concentrations of Cd-U and β2-MG, d-ROM, SOD, 8-OHdG, respectively. In contrast, an inverse, significant correlation wasobserved between Cd-U and GPX concentrations. Multiple regression analysis withadjustment for age, pack-years of smoking and hypertension indicated that IAP and 8-OHdGconcentrations were both significantly associated with Cd-B and Cd-U concentrations. GPXconcentrations were inversely and significant associated with only Cd-U concentrations. Conclusions: Significant associations between Cd concentrations (in blood and urine) on the one side andmarkers of oxidative stress and renal dysfunction on the other side were found. This suggestsearly effects and offers opportunities to develop biomarkers of oxidative stress and earlymarkers of renal injury as tools for health effect surveillance. Dept of Nephrology and Transplantation in Lund, Skane University Hospital, Sweden
FP159 PHYSICAL FUNCTION AT START OF RENAL REPLACEMENT THERAPY -INDEPENDENT PREDICTOR OF SURVIVAL
Introduction and Aims: Patients with chronic kidney disease (CKD) benefit from regular exercise training and a high level of physical function with positive effects on cardiovascular risk factors, health related quality of life and nutritional parameters as was stated in a recent Cochrane review. The aim of the present study was to examine whether physical function at start of renal replacement therapy (RRT) affects survival and whether any specific functional test has greater predictive value. Methods: In this retrospective longitudinal study, 134 patients starting RRT at our department between 01-01-1998 and 31-12-2006 were observed. Data were retrieved from medical reports and the Swedish Renal Registry. Comorbidity was categorized according to Davies (Davies et al, NDT 2002; 17:1085-92) The standardized functional test program comprised hand grip strength, isometric quadriceps strength, standing heel rise, toe lift, functional reach and stair climbing and was performed by the same physiotherapist. The patients were followed until death or until the end of the observation period.
Results: At the end of the observation period 112 (84%) patients were still alive and none were lost to follow-up. Univariate Cox regression analysis showed, as expected, a significant effect of age ( p<0.0001) and comorbidity ( p=0.028). Furthermore, hand grip strength (right p=0.0065, left p=0.0039), functional reach ( p=0.015) and standing heel rise (right p=0.011, left=0.004) all reached statistical significance in univariate analysis. In a subsequent multivariable Cox regression analysis, taking gender, age and comorbidity into account, hand grip strength left ( p=0.023) achieved statistical significance. We found hand grip strength to be an important predictor of mortality, a reduction of hand grip strength by 50% increased the hazard ratio for death fourfold. Between patient groups (alive versus deceased) there were no statistically significant differences in estimated glomerular filtration rate and laboratory test results (hemoglobin, C-reactive protein, albumin, calcium, phosphate, parathyroid hormone, creatinine and base excess). Conclusions: In this retrospective observational study, univariate analysis of hand grip strength, functional reach and standing heel rise were all significant predictors of survival. In multivariable analysis, hand grip strength left remained a significant predictor of survival after gender, age and comorbidity had been taken into account. We conclude that physical function tests at start of RRT, including both strength and balance, seem to be important predictors of survival.
FP160 LOW INTENSITY, HOME-BASED EXERCISE IMPROVES PHYSICAL CAPACITY IN DIALYSIS PATIENTS: THE EXCITE STUDY (EXCERCISE INTRODUCTION TO ENHANCE PERFORMANCE IN DIALYSIS)
Fabio Introduction and Aims: Dialysis patients are characterized by poor physical performance and reduced quality of life. The EXCITE (EXcercise Introduction To Enhance performance in dialysis) study is a randomized multicentric trial aiming to test whether a simple personalized walking exercise program prescribed in the dialysis centre but performed at home improves the degree of fitness in dialysis patients. Methods: Patients were randomized (randomization stratified by NYHA class) to normal physic activity (control group) or to two daily 10-minute walking sessions at home (exercise group). Exercise intensity in this group was guided by a metronome and gradually increased according to a predefined protocol. Functional capacity was assessed at baseline and after 6 months by the 6-minutes walking test (walk-T) and the "sit-to-stand-to sit" (Sit to Stand) test. The main study outcome was the change in physical performance as assessed by these tests at 6 months.
Results: 486 patients (39.1% of the total population of 1241) met the eligibility criteria. 318 patients (65.4%) providing informed consent were randomized to normal physical activity (n=154) or walking exercise (n=164). Physical performance at baseline was comparable in the two study groups. Two hundred and twenty seven patients (exercise n=105; control n=122) repeated functional evaluations at 6 months. Steering Committee for the 'research on the Positioning of Chronic Kidney Disease (Ckd) in Specific Health Check and Guidance in Japan' Introduction and Aims: As multiple studies demonstrated the protective effect of moderate alcohol consumption on cardiovascular disease (CVD), several studies suggested that moderate alcohol consumption may have a protective effect on chronic kidney disease (CKD). γ-glutamyltransferase (GGT), one of the alcohol-related liver enzymes along with aspartate aminotransferase (AST) and alanine aminotransferase (ALT), has recently been identified as a predictor of CKD. It is uncertain which is more associated with CKD, the liver enzyme or alcohol consumption. The purposes of the present cross-sectional study were (1) to compare the associations between proteinuria and liver enzymes and evaluate the utility of liver enzymes for identifying participants with proteinuria, stratified on drinking status, and (2) to evaluate which had the greater impact on CKD, the liver enzyme or alcohol consumption. Methods: This study was a nationwide cross-sectional survey of Japanese population undertaking specific health checkups between April, 2008 and March, 2009 . Of 506807 participants aged 40 years or older, 335168 participants (66.1%) were finally included in the present analysis after excluding 171639 participants with missing data (33.9%). To assess associations of liver enzymes with proteinuria, their prevalence ratios (PRs) and Akaike Information Criterions (AICs) were calculated using multivariate-adjusted Poisson regression models with robust variance in male non-drinkers, male drinkers, female non-drinkers, and female drinkers, separately. To clarify associations of the most useful liver enzyme and alcohol consumption with proteinuria, all participants were classified into 20 (male) and 15 (female) categories (4 (male) and 3 (female) categories of the liver enzyme × 5 categories of alcohol consumption (rarely, occasional, mild; <26 g/day, moderate; 27 -53 g/day, heavy; >54 g/day)), and PR of each category was calculated.
Results: Age of both genders were median 66 (interquartile range 60 -70) years, and eGFR of males and females were 74 ± 16 and 76 ± 16 ml/min/1.73m2, respectively. Prevalence of proteinuria was 3347 (8.1%), 7045 (7.5%), 5617 (3.9%), and 1809 (3.2%) in male non-drinkers, male drinkers, female non-drinkers, and female drinkers, respectively. In male drinkers, multivariate models identified GGT, AST, and ALT as a proteinuria-associated factor ( per 1 standard deviation (SD) log IU/L, PR 1.20 [1.18 -1.23], P<0.001; 1.14 [1.12 -1.16], P<0.001; 1.07 [1.05 -1.10], P<0.001, respectively), along with age and eGFR. The model adding on GGT showed the lowest AIC (47315), compared with AST (47395) and ALT (47509), indicating that GGT was more effective in identifying the participants with proteinuria. Results were similar to the other subgroups. Male moderate drinkers with lower GGT (<24, 25 -49 IU/L) had the lower probability of proteinuria (vs. male non-drinkers with the lowest GGT (<24 IU/L); PR 0.75 [0.65 -0.86], P<0.001; 0.90 [0.82 -0.98], P=0.011, respectively), whereas male moderate drinkers with higher GGT (>75 IU/L) had the higher probability of proteinuria (PR 1.36 [1.24 -1.48], P<0.001) ( Figure A) . The similar associations with proteinuria were observed in females ( Figure B) . Conclusions:This study suggested that participants with liver dysfunction were possibly at higher risk of proteinuria and therefore needed further examinations for CKD, irrespective of drinking status. Introduction and Aims: Albuminuria and proteinuria are markers of vascular and renal dysfunction, as well as independent predictors of increased risk of cardiovascular morbidity and mortality. Marfan syndrome (MS) is an autosomal dominant disorder caused by mutation of the gene encoding fibrillin, affecting the connective tissue and typically the cardiovascular, ocular and skeletal systems. There have been very few a report of renal involvement in Marfan's syndrome.The aim of the present study was to assess the prevalence of proteinuria and albuminuria as predictors of renal dysfunction in Marfan syndrome. Methods: We performed an observational analysis of patients with MS according Ghent criteria diagnosed in two Hospitals (H. 12 de Octubre and Hospital Vall d'Hebron). The following baseline data were compiled from medical records: age, gender, blood pressure, albuminuria, proteinuria, serum creatinine (SCr) and glomerular filtration rate (GFR) by MDRD-4, hematuria and immunological parameters. Results: Seventy-seven patients (41 M, 36 F) with MS have been evaluated to assess renal function. Mean age was 32.3 ± 10.6 (14-65 years). Renal function of patients was: serum creatinine 0.8 ± 0.2 mg/dL and a GFR (MDRD-4): 105.6 ± 26.1 mL/min. 3 patients (3.9%) had GFR<60 mL/min. Albuminuria levels was 16.6 ± 34.5 mg/24 hrs and proteinuria 0.13 ± 0.08 g/24 hrs. 9 patients (12%) of patients had albuminuria >30 mg/dL and 16 patients (20.8%) with proteinuria >0.2 g/24 hours. 9 patients (12%) had microscopic hematuria. 10 patients (13%) were hypertensive. 35 patients (45.5%) were receiving beta-blockers and 17 renin-angiotensin system blockers (22%). 10 patients (13%) had elevated levels of serum IgA. The group of hypertensive patients (N = 10), had worse renal function (SCr 0.9 ± 0.2 vs 0.7 ± 0.2 mg/dL, p 0.012 and GFR 88.9±32.2 vs 108.3±24.5 mL/min, p 0.039) that non-hypertensive. The total number of patients with renal impairment (GFR <60 mL/min) was located in hypertensive patients. The percentage of patients with elevated levels of IgA was also higher in the hypertensive group (30 vs 10.9%, p 0.101). Conclusions: The prevalence of proteinuria and albuminuria in patients with MS is higher than in the general population. Although renal function was not affected, these markers could be an early indicator of renal dysfunction. The alteration of fibrillin might be involved in the genesis of these renal effects. CKD stage 3-5 patients who received medical prescription more than 3 months were divided into dipyridamole treated and untreated groups. We used propensity-score weighting to adjust for difference in all covariates (sex, age, primary renal diseases, comorbid diseases, life styles, baseline clinical characteristics and laboratory data, and drugs) between the two groups. Cox proportional hazard models were used to evaluate the association of dipyridamole and outcomes after adjusting propensity score and all covariates. Results: Among the total 3074 subjects analyzed, 871 patients (28.3%) had been treated with dipyridamole. After adjustment by inverse probability of treatment weighted (IPTW) estimator, the baseline characteristics between the two groups were similar except the causes for primary renal diseases and alcohol use. The medication of renin-angiotensin blockage, other antihypertensive treatment, statin and oral anti-diabetic treatment were also similar between two groups. Majority of patients were female (64%) with mean age of 63.0 years, and averaged eGFR of 25. Cochrane Renal Group, Sydney, Australia
FP161 Figure 1
Introduction and Aims: International treatment guidelines suggest achieving target levels of serum phosphorus, parathyroid hormone (PTH) and calcium in people with chronic kidney disease (CKD). We evaluated the evidence that specifically targeted biomarker levels (serum phosphorus, parathyroid hormone, and calcium) improved clinical outcomes in people with CKD. Methods: We conducted a systematic review of randomized controlled trials that reported achievement of serum targets for phosphorus, PTH, and calcium in adults with CKD and that reported relevant clinical outcomes (mortality, fracture, kidney function, and withdrawal due to treatment toxicity). We systematically searched Cochrane and Embase databases without language restriction to September 2010. We also included randomized trials of interventions (vitamin D compounds, calcimimetics, and phosphate-binding agents) that reported serum biochemical for phosphorus, PTH, and calcium at study end in people with CKD and that reported relevant clinical outcomes. We summarized the effects of specific biochemical targets on specified outcomes as randomized interventions using random-effects meta-analysis. We also summarized the non-randomized associations between the proportion of participants achieving biomarker targets and clinical outcomes using two-dimensional arrow plots. Subgroup and meta-regression analyses to evaluate the effects of patient and intervention characteristics on treatment effects were not possible due to insufficient data. Trial risk of bias was evaluated using standard methods. Results: On the basis of 158 trials (24,965 people with CKD) evaluating interventions on serum biomarker values, no consistent associations between the proportion of participants achieving a biomarker target and clinical outcomes (total and cardiovascular mortality, fracture or end-stage kidney disease) were observed in low-quality or insufficient evidence. Similarly, no consistent associations between biomarker values at study end and clinical outcomes were observed. Specifically, an increasing proportion of participants achieving a serum PTH target with treatment was not consistently associated with lower mortality (Figure) but may be associated with increased withdrawal from treatment due to adverse events. Conclusions: Targeting specific levels of phosphorus, PTH, and calcium is not consistently associated with improved clinical outcomes in adults with CKD. Treatment to specific PTH targets may be associated with treatment-related toxicity. University "Federico II". Napoli,
FP165 EFFECT OF PHOSPHATE BINDER THERAPY ON MORTALITY IN PRE-DIALYSIS PATIENTS
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University of Naples "Federico II". Naples. Italy Introduction and Aims Coronary artery calcifications ( CAC ) are prevalent and severe in all stages of chronic kidney disease. In pre-dialysis patients (NDD-CKD ), CAC display an accelerated progression that is strongly associated to poor outcomes such as cardiovascular events and faster inception to dialysis. Despite the clinical relevance of the latter findings, there is no study aimed at establishing improvement of outcomes by reducing CAC progression in NDD-CKD. The main aim of the present study was to ascertain whether outcomes may be ameliorated by reducing CAC progression in NDD-CKD patients treated with either sevelamer or calcium carbonate. Methods: This study has been performed in a sub-group of outpatients from a larger multicenter, prospective, randomized study. Inclusion criteria were: age > 18 years, CKD stage 2-4, presence of CAC. Exclusion criteria were: heart failure and/or coronary artery disease, history of myocardial infarction, coronary bypass, angioplasty, stroke, arrhythmia. Patients were treated either with calcium carbonate or sevelamer. Routine blood chemistry was assessed at enrollment and every six months. Clinicians were instructed to control parameters of mineral metabolism according to their everyday practice; targets taken in account were those suggested by K/DOQI guidelines that were available at the start of the study. Recorded events were: sudden death, fatal and not fatal myocardial infarction, other-cause mortality, and inception of dialysis. The scheduled follow-up for evaluation of events was 36-month long. Coronary Calcium Score (CAC-Score) was assessed by computed tomography at study entry, on 6th, 12th, 24th month. Progression of CAC was evaluated as (1) absolute change of CAC-score (change between 24th month and baseline) and (2) annualized progression that take in account the time between scans. Patients were defined progressors when the difference between the last and the baseline CAC-score was = 15%. Data are expressed as mean ± standard deviation. Kaplan-Meier survival curves were created and a long-rank test used for comparisons. Multivariable Cox regression analysis was performed to assess factors significantly associated to events risk. Results: Enrolled patient were n. 113 (n.47 and n. 66 treated with calcium and sevelamer, respectively). Baseline CAC-score was 388±413 and 306±382 AU in calcium and sevelamer-treated patients, respectively; p=0.27). CAC-score did not progress in n.1 and in n. 22 patients treated with calcium and sevelamer, respectively; p=0.0001). All survival curves were significantly (p=0.001) worse in calcium-treated patients. Conclusions: Phosphate binder choice strongly influences events in NDD-CKD patients with CAC. Sevelamer offers benefits on survival and inception to dialysis. The benefits overcome the negative effects of CAC progression. such as radiation exposure and inconvenience. Our aim was to identify a more readily-measurable predictor of incident CVD among four vascular calcification-related factors, osteoprotegerin (OPG), fibroblast growth factor 23, fetuin-A, and fetuin-mineral complex (FMC). Methods: In this prospective cohort study, we enrolled 97 diabetic outpatients with chronic kidney disease (CKD) in a nephrology department in Japan. We measured CACS by multi-detector computed tomography. The endpoint was defined as a fatal or non-fatal CVD requiring hospitalization. Multiple imputation method was carried out for missing values. After confirming that CACS predicts CVD with adjustment for conventional risk factors, additional adjustment of which biomarker changed the coefficient of CACS by =15% was scrutinized in Cox proportional hazards models. We compared model performance between models with either that biomarker or CACS by employing C-statistics, Bayesian information criterion (BIC), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Results: Median estimated GFR (eGFR) was 25 mL/min/1.73m2. During a median follow-up period of 5.0 (IQR, 2.0-5.8) years, 32 patients developed the endpoint. At baseline, only OPG and FMC were associated with CACS. In a multivariable Cox model, CACS, treated as continuous or categorical variable, was significantly related to CVD after adjustment for age, sex, prior CVD, eGFR, urinary protein, duration of diabetes, and systolic blood pressure (hazard ratios (HRs) [95% confidence intervals (CIs)], 1.75 [1.03-2.99] per SD increase of ln (CACS+1) and 4.40 [1.10-17.7] in the highest vs. lowest quartile). Among four factors of our interest, only OPG adjustment changed the coefficient of CACS by =15% (22.9%), leading to the elimination of its significance. Comparing the models including either CACS or OPG, the effect sizes were much higher for OPG than for CACS (HRs [95%CIs] , 2.14 [1. 35-3.39] per SD increase of in the highest vs. lowest quartile). Unadjusted Kaplan-Meier curves (Figure) showed that patients in higher quartiles of CACS or OPG were in higher risk for CVD event. The separation of curves for OPG quartiles were observed much earlier than that for CACS quartiles, indicating a higher resolution in risk stratification by OPG. From the perspective of C-statistics, BIC, NRI, and IDI, model performance was better with a model containing OPG than that with CACS. Conclusions: In predicting incident CVD, OPG rather than CACS should be measured in diabetic patients with CKD. Results: The mean age was 62.3 years, 59.1% were female, and the mean estimated GFR was 30.7 mL/min/1.73m2. During a median follow-up of 2.7 years, 346 (9.5%) patients died and 1076 (29.6%) commenced renal replacement therapy (RRT). In logistic regression, hematuria had positive correlation with histories of urinary tract infection [OR 1.35 Results: During a 46 month follow-up, 308 patients died (CV 54%). In analyses adjusting for age, sex, smoking, cholesterol, C-reactive protein, waist circumference and BMI, both HOMA-IR and HOMA-AD predicted all cause (P=0.003 and P=0.01) and CV mortality (P<0.001 and P=0.004). All other indexes of IR (QUICKI, McAI and LAR) had no independent predictive power for study outcomes. Conclusions: Independently of other risk factors, two simple indexes of insulin resistance, HOMA and HOMA adjusted for adiponectin levels, predict all causes and cardiovascular mortality in stage 5D CKD patients. These relationships points to insulin resistance as a relevant pathway conducive to adverse clinical outcomes in this population. HOMA per se (without adjustment for adiponectin) holds predictive power at least equal to that adiponectin-adjusted HOMA and may be applied in large scale epidemiological studies in this population. Introduction and Aims: Chronic renal failure (CRF) and imposed hemodialysis (HD) induce interesting effects on visual system. This study was planned to evaluate the effects of different changing metabolic parameters on intra ocular pressure (IOP) in hemodialysis patients Methods: This descriptive cross sectional study was conducted on 65 HD patients. Demographic information including age, gender, underling systemic or ocular diseases or surgeries, HD duration and frequencies in addition to levels of blood FP166 Figure 1: pressure (BP), body weight, blood urea, sodium (Na), potassium (K) blood sugar (BS), before and after HD and KT/V values were recorded. Patients with any glaucomatous medications or conditions were excluded. Results: In present study 130 eyes of 65 HD patients (38 male and 27 female) with the age ranges of 24-90 (mean 60.27±16.66) years were evaluated. Mean post HD, IOP (12.73 mmHg) were significantly lower than mean pre HD, IOP (13.50 mmHg) (P=0.023). Mean IOP levels in the first and second hour (12.32 and 11.83 mmHg respectively) of HD sessions was significantly lower than the mean pre dialysis IOP (13.50 mmHg) (P=0.000 and 0.000 respectively). In addition mean IOP in second hour (11.83 mmHg) was still significantly lower than the first hour of HD (12.32 mmHg) (P=0.000). In non-diabetic (but not in diabetic) patients, IOP significantly decreased after HD .Mean BS levels were significantly decreased after HD (P=0.000) and there were meaningful relationship between IOP and BS changes after HD (P=0.040 ( Conclusions: BS changes significantly decreased IOP in HD patients without glaucomatous disorders. There weren't any meaningful relationship between changes of serum Na and K, BP, blood urea, KT/V, weight, duration of HD and underlying diseases with IOP changes before and after HD.
FP167 HEMATURIA IS A RISK FACTOR FOR END STAGE RENAL DISEASE IN CHRONIC KIDNEY DISEASE PATIENTS
FP170 EVALUATION OF AN INSTRUMENT FOR SCREENING PATIENTS AT RISK FOR CHRONIC KIDNEY DISEASE: TESTING SCORED (SCREENING FOR OCCULT RENAL DISEASE) IN PORTUGUESE POPULATION
Introduction and Aims: The prevalence of chronic kidney disease (CKD) is increasing worldwide and represents a social and economic burden in many countries. Since it is asymptomatic until late stages, CKD is underdiagnosed and referral to the nephrologist occurs late in the progression of the disease resulting in poor outcomes. Identification of individuals at risk of CKD becomes important in this scenario, allowing early implementation of strategies that improve survival. In 2007, Bang et al. developed a screening tool, SCORED (SCreening for Occult REnal Disease), that identifies individuals with high probability of occult CKD based on the answer to 9 clinical and demographic questions. Our aim was to analyze the performance of SCORED in identifying subjects at risk of CKD in a sample of Portuguese population. Methods: The SCORED tool was applied to volunteers that attended the World Kidney Day 2011 event in Torres Vedras, Portugal. Demographic and clinical data were collected, and the SCORED questionnaire was filled in. Individuals with SCORED score =4 were considered at risk of CKD. Within 3 months, the volunteers had an appointment in the Nephrology Department in which blood and urine samples were collected. Glomerular filtration rate (GFR) was estimated according to the CKD-EPI equation and Urinary albumin-to-creatinine ratio (UACR) was accessed. CKD was considered if eGFR<60mL/min/1.73m2 or in the presence of UACR>30mg/g. The risk of CKD obtained from the SCORED questionnaire was compared with the presence of CKD after eGFR and UACR were accessed. Results: Eighty-eight volunteers were evaluated, 60 (68.2%) of whom were identified as being at risk of CKD according to the SCORED. Only 47 (53.4%) subjects attended the appointment at the Nephrology Department. When considering CKD in the presence of GFR<60mL/min/1.73m2, SCORED had a sensibility of 100%, specificity of 24.3%, positive predictive value of 26.4% and negative predictive value of 100%. Considering CKD if GFR<60mL/min/1.73m2 or UACR>30mg/g were present, this tool obtained a sensibility of 89.5%, specificity of 21.4%, positive predictive value of 43.6% and negative predictive value of 75.0%. Conclusions: Our results suggest that SCORED, besides inexpensive and easy to perform, seems to be effective in the recognition of subjects that, according to their clinical condition, have high probability of CKD and should proceed to further clinical assessment. The small size of the sample does not allow us to conclude whether or not SCORED should routinely be used as a screening procedure but it may represent a useful tool for primary care physicians before referral to nephrologists.
Introduction and Aims: Using applanation tonometry, pulse wave analysis (PWA) can be performed. PWA derived from radial artery can provide information about hemodynamic parameter subendocardial viability ratio (SEVR) or the Buckberg index, which is a non-invasive estimate of myocardial workload and perfusion and is measure of the ability of the arterial system to meet the heart`s energy requirements. Albuminuria and chronic kidney disease (CKD) are associated with increased risk of clinical cardiovascular disease (CVD). The purpose of our study was to evaluate the relationship between SEVR and albuminuria in CKD patients. Methods: PWA and SEVR measurements using applanation tonometry were performed (SphygmoCor, AtCor Medical, Ltd., Sydney, Australia). For PWA, an average radial pressure waveform was generated from at least 10 seconds of sequential radial pressure waveforms. PWA was used to determine SEVR in 63 patients (45 men, 18 women; age 22-88 years; mean 61.33±13.27) with different stages of CKD (cystatin C 0.66-4.02 mg/L; mean 2.11±0.86). Four (6.3%) patients were habitual smokers, 23 (36.5%) patients were former smokers and 17 (27%) patients were diabetics. Albuminuria was determined with the urinary albumin/ creatinine ratio (UACR). 24-hour ambulatory BP measurements (ABPM) were performed using a non-invasive ABPM monitor (Schiller BR-102 plus, Schiller AG, Switzerland Results: Age (HR 0.66, 95% CI 0.47-0.94)) and gender (HR for men vs. women is 2.24, 95% CI 1.4-3.6)) were significantly associated with the development of ESRD among newly diagnosed SLE patients and the overall 6-year incidence rate is 2.5%. In the survival analysis post the development of ESRD, patients with SLE revealed a higher hazard (HR 1.3, 95% CI 0.71-2.39). In particular, patients with SLE demonstrated a significant hazard (HR 2.73, in the younger population (less than 40 years old). Our limitation included registration bias, lack of laboratory data, and exact cause of death from the national database.
Conclusions: Age and gender were risk factors for the development of ESRD among newly diagnosed SLE patients. Female patients, compared with male patients, were less likely to develop ESRD and had better survival post the development of ESRD. After entering ESRD, SLE patients younger than 40 years old had the worst 5-year survival rate.
FP173 THE SIGNIFICANCE OF HYPERURICEMIA ON NEPHROCALCINOSIS BY ULTRASONOGRAPHY IN NON-PROTEIURIC CKD OF GENERAL POPULATION
health check population, non-proteinuric individuals with low eGFR were not observed scarcely.But the pathogenesis was not clarified.We reported the hyperuricemia is the the risk factor for non-proteinuric CKD by cohort study. The prevalence of nephrocalcinosis in subject with non-preoteinuric CKD (eGFR<60) was 6.7%, and higher than the prevalence (4.9%) in non-CKD significantly ( P=.018). In the nephrocalcinosis group of CKD, SUA level is 6.8 ±1.3mg/dl ,SCr(serum creatinine) level is 1.09 ±0.16 and in non-nephrocalcinosis group of CKD, these are 6.3±1.4mg/dl,1.02±0.18mg/dl respectively. In the nephrocalcinosis group, SUA with significance ( p=0.019) showed high value and SCr showed high value with significance( p=0.033) after adjusted for age and gender. No significant difference in urine pH, SBP, TG, HDL and FBG levels were shown between with and without nephrocalcinosis groups. In the multivariable logistic analysis for nephrosclerosis, SUA, SBP, and urine pH were significant risk factors. The odds ratios were 1.101 (P=0.002), 1.011(P<0.001), and 0.883(P=0.023), respectively. Longitudinal analyses with multivariable Cox proportional hazard model showed that only SUA had a significant hazard ratio, 1.204 (P=0.015), for nephrocalcinosis. Conclusions: Hyperuricemia, hypertension and acidic urine are related and especcially, hyperuricemia is the risk factor to the non-proteinuric CKD and nephrocalcinosis. Hyperuricemic-nephrocalcinosis is suggested as pathogenesis of non-proteinuric CKD. Further investigation is necessary to be sure that control of hyperuricemia preserves renal function and decreases of nephrocalcinosis. Introduction and Aims: Cardiovascular disease is the leading cause of death in patients with chronic kidney disease (CKD). Increased inflammation is common in patients with CKD and is associated with increased adverse cardiovascular (CV) events. Numerous biologic markers of inflammation including C-reactive protein (CRP) and interleukin-6 have been studied with an attempt to prognosticate patients in terms of adverse cardiovascular outcomes. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were used to predict survival in patients with cardiovascular diseases and malignancy. We aimed to evaluate if PLR would provide additional data regarding development of cardiovascular events in addition to inflammatory markers such as CRP in patients with stage 3 to 5 CKD. We also investigated relation of PLR with endothelial function. Methods: 242 subjects with stage 3-5 CKD were followed for a mean of 39 months. There were 77 patients with stage-3, 79 patients with stage-4, and 86 patients with stage-5 CKD. All stage-5 patients were predialytic. Fatal and nonfatal CV events were recorded during this period. PLR at baseline was determined from complete blood count differential. Endothelial function (flow mediated dilation, FMD) and CRP were determined along with routine biochemistry. Results: A total of 72 composite (20 fatal and 52 nonfatal) CV events occurred during the follow-up period. Cardiovascular mortality (n=20) was defined as death due to coronary heart disease (13), sudden death (3), stroke (3) and complicated peripheral vascular disease (1). In addition to cardiovascular deaths, 52 non-fatal cardiovascular events were registered as follows: stroke (18); myocardial infarction (29); peripheral vascular disease (4) and aortic aneurysm (1). PLR as well as platelets and lymphocytes particularly showed significant decrease from stage-3 CKD to stage-5. Univariate and multivariate cox analyses showed that PLR was a significant independent predictor of composite CV events. Univariate analysis demonstrated that PLR predicts composite CV events independent of FMD, lymphocytes and history of diabetes (hazard ratio 1.08; 95% CI; p<0.001). The hazard ratio was 1.03 for PLR after adjustment for age, sex, eGFR, CRP, haemoglobin, platelet, lymphocyte, diabetes, and medical history of cardiovascular disease at baseline. PLR was inversely correlated with FMD (r=-0.34; CI 95%; p<0.001). Kaplan-Meier analysis showed that PLR = 0.147 was related to a significantly decreased survival time. The survival rate was 99% in the group with PLR < 0.147 compared to 84% in the arm with PLR = 0.147 ( p<0.001 by log-rank test). Conclusions: PLR is independently related to endothelial dysfunction and can predict composite CV endpoints independent of traditional confounding factors in patients with moderate to severe CKD. Decreased PLR above 0.147 may be used as a complementary prognostic marker for predicting cardiovascular events in patients with CKD. Introduction and Aims: It is well-known that hyperkalemia is associated with the progression of chronic kidney disease. Hypokalemia-induced tubulointerstitial disease was also documented in basic research and hypokalemia was reported to be associated with adverse outcomes in patients with cardiovascular diseases and recently in chronic kidney disease (CKD). However, in earlier CKD stages, the role of serum potassium and the reason for the prognostic value of hypokalemia are less understood. Thus, we investigate whether hyperkalemia or hypokalemia is a risk factor for adverse outcomes in mild-moderate CKD population. Methods: Between November 2002 and June 2009, 3659 patients received the integrated CKD care in Kaohsiung Medical University Hospital. A total of 2500 subjects in CKD stage 1-4 were classified into five quintiles based on serum potassium: Q1 to Q5 with the cut-off level at 3.82, 4.1, 4.33, and 4.62 mmol/L, respectively. Chi-square test, t-test, Kaplan-Meier survival analysis and multivariate cox regression analysis were used and p value less than 0.05 was considered as significant. Results: Majority of patients were female (64%), had diabetes (41.8%) with mean age of 62.4 years, and averaged eGFR of 40.6 ml/min per 1.73 m2. During a median 2.7-year follow-up, 299 (12.0%) and 223 (8.9%) patients reached end-stage renal disease (ESRD) and mortality, respectively. There was a robust trend of higher mean BP, more common use of diuretics, and less frequent use of anti-hypertensive medication and renin-angiotensin inhibitors in patients with lower serum potassium. The prevalence of nephrotic range proteinuria was higher in both the lowest and hightet quintiles. Serum potassium was inversely correlated with female gender, diuretics use, eGFR, mean BP, bicarbonate, CRP and hemoglobin. Hypokalemia (<4.1 mmol/L) was significantly associated with ESRD even after adjustments for baseline variables and nutritional factors with hazard ratios (HRs) of the lower quintiles (Q1 vs Q3) 1.63 [95% CI, 1.02-2.59, p=0.03] and (Q2 vs Q3) 1.58 [95% CI, 1.02-2.45, p=0.03], respectively. The lowest quintile (Q1) was significantly associated with faster yearly decline in eGFR with the odds ratio 1.54 [95% CI, 1.07 to 2.22, p=0.01]. The risk of hypokalemia remained borderline significance for mortality and cardiovascular events but the association was mitigated with the adjustment for serum albumin. Hyperkalemia was associated with elevated risk of ESRD but adding nutritional and inflammatory covariates to the model decreased this association. The associations between hyperkalemia and mortality and cardiovascular events were not significant. Conclusions: Both hypokalemia and hyperkalemia were significantly asscociated with increased risk of progression towards ESRD in our mild to moderate CKD population. Whether over-diuretics use, under-renin-angiotensin blockage and malnutrition are related to the prognostic value of hypokalemia may need further study. , from 18 to 88 y.o. were screened. Studied parameters were: fasting blood sugar, serum creatinine, total cholesterol, urine sample for creatinine and microalbuminuria/albuminuria (MA/A). We collected data for educational level, presence of arterial hypertension and diabetes. Arterial pressure was measured and BMI was calculated. As presence of data for CKD we accepted MA/A (UACR>2,5
FP174 PLATELET TO LYMPHOCYTE RATIO INDEPENDENTLY PREDICTS CARDIOVASCULAR EVENTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE
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Introduction and Aims: RDX5791 is a first-in-class minimally systemic, small molecule NHE3 inhibitor in clinical development for the treatment of sodium (Na) and fluid overload-related diseases. The intestinal Na+/H+ antiport protein NHE3 plays a key role in the uptake of Na from the intestinal lumen. RDX5791 decreases NHE3-mediated intestinal Na transport leading to enhanced fecal excretion and reduced urinary excretion. In a randomized, double-blind, placebo-controlled, ascending-dose study, RDX5791 was very well tolerated and exhibited minimal to no systemic absorption. The purpose of this study was to evaluate the safety, tolerability and pharmacodynamics (PD) of different RDX5791 dosing regimens. Methods: A randomized double-blind, placebo-controlled study was performed in 90 healthy volunteers treated for 7 days with either 30 mg QD; 15, 30, or 60 mg bid; or 30 mg tid (12 treated, 3 placebo/cohort) RDX5791. An additional cohort was examined where the dose was escalated to effect. Safety assessments were performed and included vital signs, ECGs, hematology, serum chemistry evaluations as well as adverse event assessments. The PD of RDX5791 was assessed by measuring stool and urine Na, stool frequency, weight, and consistency. Results: RDX5791 was very well tolerated and there were no SAEs observed and very few adverse events; urine and serum electrolytes were within the normal range. RDX5791 induced a significant increase in stool Na with a concomitant decrease in urine Na (shown below). At a total dose of 30 mg/day, 15 mg bid produced 3-fold greater stool Na excretion than 30 mg QD. For the bid dose regimen, the dose response relationship was flat as 15 mg produced higher stool Na output than 30 mg. When calculated over the 7-day period and corrected from baseline, the cumulated stool Na output was 21 mmol for placebo and between 205 to 345 mmol for bid administration and the cumulated Na urinary output was 166 mmol for placebo, and between 363 and 591 mmol for bid administration. For bid administration, response rates among subjects on fixed dose regimens ranged from 50-60%. In the treat-to-effect cohort, 92% of the subjects (11 of 12) responded to dose escalation. Except for the 60 mg bid dose, all doses produced stool frequency and stool consistency within the normal range; stool weight correlated with stool Na output.
Conclusions: RDX5791 dosed bid or tid was well tolerated, increased fecal Na by 30-50 mmol/day and decreased urinary Na of 40-60 mmol/day. A high response rate was achieved by titrating the drug to effect. The magnitude of Na output (inhibition of dietary sodium absorption), high tolerability and absence of effects on other electrolytes (K, Ca and acid-base) are promising attributes of RDX5791 in the context of treating fluid and salt overload. RDX5791 has the therapeutic potential in ESRD patients to reduce interdialytic weight gain and its associated cardiovascular and mortality risks, as well as in CKD and congestive heart failure patients to manage hypertension and resorb edema. Student Hospital-Cairo University-Cairo-Egypt, Introduction and Aims: Pulmonary hypertension (PHT) is one of cardiovascular complications reported in chronic kidney disease (CKD) patients especially those undergoing hemodialysis. Multiple factors act together leading to its occurrence including abnormalities in vasoactive peptides. The aim of this work was to study the prevalence of PHT in CKD patients both on conservative treatment and on hemodialysis and its relation to total plasma nitric oxide (NO). Pulmonary hypertension (PHT) is one of cardiovascular complications reported in chronic kidney disease (CKD) patients especially those undergoing hemodialysis. Multiple factors act together leading to its occurrence including abnormalities in vasoactive peptides. The aim of this work was to study the prevalence of PHT in CKD patients both on conservative treatment and on hemodialysis and its relation to total plasma nitric oxide (NO). Methods: 92 subjects were included in the study, who were divided into three groups; group I included 32 CKD patients on conservative treatment, group II included 30 CKD patients treated by hemodialysis three times/week and group III included 30 healthy controls. All patients were subjected to blood tests including plasma NO testing by ELISA. Doppler echocardiography was performed for evaluation of pulmonary artery systolic pressure (PASP). Results: PHT (PASP>35mmHg) was present in 6/32 (18.75%) of group I patients , 10/30 (33.3%) of group II patients and none of group III controls. PASP was significantly higher ( p<0.001) and plasma NO was significantly lower in group II patients ( p<0.001) than among other groups. In group I patients PASP was negatively correlated with plasma NO ( p<0.001), but positively correlated to blood urea( p=0.009), and serum creatinine ( p=0.04). In group II patients there was no significant correlation between PASP and plasma NO ( p=0.8). Conclusions: PHT is more prevalent among hemodialysis patients than among CKD patients. NO might play a role in development of PHT in CKD patients while its role in hemodialysis patients is still unclear. Introduction and Aims: Depression is associated with mortality and cardiovascular events in the general population. Numerous studies evaluate depression in people with chronic kidney disease (CKD) but provide variable estimates of prevalence and associations with clinical outcomes. We summarize the available evidence on the prevalence of and outcomes associated with depression in people with CKD. We FP177 Table 1 Stool and urine Na defined as: [daily Na average output on day 2-7 minus daily Na average output on day -3 to -1] corrected from placebo. 1-way ANOVA, *: p<0.05; **: p<0.01; ***:p<0.001 vs. placebo
